NIHR Biomedical Research Centre, UCL Institute of Ophthalmology and Moorfields Eye Hospital, London, United Kingdom.
Apollo Therapeutics, Stevenage, United Kingdom.
Stem Cells Transl Med. 2019 Aug;8(8):775-784. doi: 10.1002/sctm.18-0263. Epub 2019 Apr 29.
Glaucoma is one of the leading causes of blindness, and there is an ongoing need for new therapies. Recent studies indicate that cell transplantation using Müller glia may be beneficial, but there is a need for novel sources of cells to provide therapeutic benefit. In this study, we have isolated Müller glia from retinal organoids formed by human induced pluripotent stem cells (hiPSCs) in vitro and have shown their ability to partially restore visual function in rats depleted of retinal ganglion cells by NMDA. Based on the present results, we suggest that Müller glia derived from retinal organoids formed by hiPSC may provide an attractive source of cells for human retinal therapies, to prevent and treat vision loss caused by retinal degenerative conditions. Stem Cells Translational Medicine 2019;8:775&784.
青光眼是导致失明的主要原因之一,因此我们一直在寻求新的治疗方法。最近的研究表明,利用 Müller 胶质细胞进行细胞移植可能具有治疗效果,但我们需要寻找新的细胞来源以发挥治疗作用。在本研究中,我们从体外诱导多能干细胞(hiPSC)形成的视网膜类器官中分离出 Müller 胶质细胞,并证明了它们在 NMDA 耗尽的大鼠中部分恢复视觉功能的能力。基于目前的研究结果,我们认为 hiPSC 形成的视网膜类器官衍生的 Müller 胶质细胞可能为人类视网膜治疗提供一种有吸引力的细胞来源,以预防和治疗由视网膜退行性疾病引起的视力丧失。Stem Cells Translational Medicine 2019;8:775&784.